Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NEVRO CORPNVRO · Entity 12422 | Chief Financial Officer | June 04, 2020 | June 08, 2020 |
| OOMA INCOOMA · Entity 2473 | Director | June 04, 2026 | June 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NEVRO CORP
Report date June 04, 2020 · Filed June 08, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 59,179 |
Reported balance
After 2020-06-04 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-06-04 · Tax withholding · Disposed 2,311 · Balance 59,179 F1: Includes 12,491 restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes 12,491 restricted stock units.
OOMA INC
Report date June 04, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 250,824 |
Reported balance
After 2026-06-04 transaction · row 1
1 source rowRow 1 · 2026-06-04 · Grant · Acquired 9,743 · Balance 250,824 F1: 100% of the total number of restricted stock units shall vest on the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continued service as a member of the Board. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the total number of restricted stock units shall vest on the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continued service as a member of the Board.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Arcellx, Inc.
Report date April 28, 2026 · Filed April 28, 2026
Section 16 reporting ended · disclosed 2026-04-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy trust | 0 |
Reported balance
After 2026-04-28 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-04-28 · Other · Disposed 5,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026 (the "Merger Agreement"), by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for (x) $115.00 per share ("Closing Amount"), net to the seller in cash, without interest, subject to withholding tax, plus (y) one contractual contingent value right (a "CVR"), which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, pursuant to the terms and subject to the conditions of a contingent value rights agreement. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $69.87 · Expires 2035-03-18 | Direct | 0 |
Reported balance
After 2026-04-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-28 · Disposition to issuer · Disposed 16,829 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than the Closing Amount, was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $63.68 · Expires 2035-05-29 | Direct | 0 |
Reported balance
After 2026-04-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-28 · Disposition to issuer · Disposed 1,784 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than the Closing Amount, was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026 (the "Merger Agreement"), by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for (x) $115.00 per share ("Closing Amount"), net to the seller in cash, without interest, subject to withholding tax, plus (y) one contractual contingent value right (a "CVR"), which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, pursuant to the terms and subject to the conditions of a contingent value rights agreement. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent.
F2: Pursuant to the Merger Agreement, each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than the Closing Amount, was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 04, 2026 Filed Jun 8, 2026 22:59 UTC | OOMA INC OOMA · Entity 2473 | GrantCommon Stock | 9,743 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-262429 · ownership.xml · nonDerivative · entry 1 Galligan Andrew H · CIK 0001417976 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,824 F1 · shares: 100% of the total number of restricted stock units shall vest on the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continued service as a member of the Board. Read SEC document |
| April 28, 2026 Filed Apr 28, 2026 20:26 UTC | Arcellx, Inc. ACLX · Entity 15294 | Disposition to issuerStock Option (right to buy) · Derivative | 1,784 | Not disclosed Strike: $63.68 | Not disclosed |
DisclosureSEC source: 0001417976-26-000002 · form4-04282026_080447.xml · derivative · entry 3 Galligan Andrew H · CIK 0001417976 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,784 shares Expires 2035-05-29 F2 · price: Pursuant to the Merger Agreement, each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than the Closing Amount, was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than the Closing Amount, was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. Read SEC document |
| April 28, 2026 Filed Apr 28, 2026 20:26 UTC | Arcellx, Inc. ACLX · Entity 15294 | Disposition to issuerStock Option (right to buy) · Derivative | 16,829 | Not disclosed Strike: $69.87 | Not disclosed |
DisclosureSEC source: 0001417976-26-000002 · form4-04282026_080447.xml · derivative · entry 2 Galligan Andrew H · CIK 0001417976 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,829 shares Expires 2035-03-18 F2 · price: Pursuant to the Merger Agreement, each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than the Closing Amount, was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. F2 · derivative.exercise_date: Pursuant to the Merger Agreement, each outstanding Company stock option ("Company Option"), whether or not vested, and which had a per share exercise price less than the Closing Amount, was canceled and converted into the right to receive (i) a lump sum cash payment equal to (x) the excess of (a) the Closing Amount over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to the effective time of the Merger, and (ii) one contractual contingent value right for each share subject to such Company Option immediately prior to the effective time of the Merger. Read SEC document |
| April 28, 2026 Filed Apr 28, 2026 20:26 UTC | Arcellx, Inc. ACLX · Entity 15294 | OtherCommon Stock | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001417976-26-000002 · form4-04282026_080447.xml · nonDerivative · entry 1 Galligan Andrew H · CIK 0001417976 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · By trust Disclosed balance after: 0 F1 · price: Pursuant to the Agreement and Plan of Merger, dated February 22, 2026 (the "Merger Agreement"), by and among Arcellx, Inc. ("Company"), Gilead Sciences, Inc. ("Parent"), and Ravens Sub, Inc., a wholly owned subsidiary of Parent ("Purchaser"), the shares of common stock of Company that were tendered to Purchaser prior to the expiration time of the offer were exchanged for (x) $115.00 per share ("Closing Amount"), net to the seller in cash, without interest, subject to withholding tax, plus (y) one contractual contingent value right (a "CVR"), which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, pursuant to the terms and subject to the conditions of a contingent value rights agreement. After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Read SEC document |
| June 23, 2025 Filed Jun 24, 2025 22:12 UTC | OOMA INC OOMA · Entity 2473 | SaleCommon Stock | 12,407 | $12.43 | $154,276.08 |
DisclosureSEC source: 0000950170-25-089617 · ownership.xml · nonDerivative · entry 1 Galligan Andrew H · CIK 0001417976 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 241,081 F1 · kind: The range of prices for the shares of Common Stock sold is from $12.285 to $12.51. The Reporting Person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price. Read SEC document |
| June 05, 2025 Filed Jun 9, 2025 23:37 UTC | OOMA INC OOMA · Entity 2473 | GrantCommon Stock | 11,556 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-083984 · ownership.xml · nonDerivative · entry 1 Galligan Andrew H · CIK 0001417976 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 253,488 F1 · shares: 100% of the total number of restricted stock units shall vest on the date of the Company's 2026 annual stockholder meeting, subject to the Reporting Person's continued service as a member of the Board. Read SEC document |
| May 29, 2025 Filed May 30, 2025 20:24 UTC | Arcellx, Inc. ACLX · Entity 15294 | GrantStock Option (right to buy) · Derivative | 1,784 | $0.00 Strike: $63.68 | $0.00 |
DisclosureSEC source: 0001415889-25-014994 · form4-05302025_080548.xml · derivative · entry 1 Galligan Andrew H · CIK 0001417976 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,784 Underlying: Common Stock · 1,784 shares Expires 2035-05-29 F1 · derivative.exercise_date: Subject to the reporting person's continuing to be a Service Provider (as defined in the 2022 Equity Incentive Plan) through such applicable vesting date, one hundred percent (100%) of the shares subject to the award will vest on the earlier to occur of May 29, 2026 or the next annual meeting of stockholders. Read SEC document |
| March 18, 2025 Filed Mar 20, 2025 21:15 UTC | Arcellx, Inc. ACLX · Entity 15294 | GrantStock Option (right to buy) · Derivative | 16,829 | $0.00 Strike: $69.87 | $0.00 |
DisclosureSEC source: 0001415889-25-008692 · form4-03202025_090323.xml · derivative · entry 1 Galligan Andrew H · CIK 0001417976 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,829 Underlying: Common Stock · 16,829 shares Expires 2035-03-18 F1 · derivative.exercise_date: Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2022 Equity Incentive Plan) through each applicable vesting date, one-third (1/3rd) of the shares subject to the option will vest each year following the Equity Grant Date on the same day of the month as the Equity Grant Date (or, if there is no corresponding day in a particular month, then the last day of the month) over three (3) years. "Equity Grant Date" shall mean March 18, 2025. Read SEC document |
| December 17, 2024 Filed Dec 19, 2024 21:08 UTC | OOMA INC OOMA · Entity 2473 | Exercise / conversionStock Option (right to buy) · Derivative | 35,000 | $0.00 Strike: $6.04 | $0.00 |
DisclosureSEC source: 0000950170-24-138441 · ownership.xml · derivative · entry 3 Galligan Andrew H · CIK 0001417976 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2024-12-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| December 17, 2024 Filed Dec 19, 2024 21:08 UTC | OOMA INC OOMA · Entity 2473 | SaleCommon Stock | 14,824 | $14.56 | $215,837.44 |
DisclosureSEC source: 0000950170-24-138441 · ownership.xml · nonDerivative · entry 2 Galligan Andrew H · CIK 0001417976 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 241,932 Read SEC document |
| December 17, 2024 Filed Dec 19, 2024 21:08 UTC | OOMA INC OOMA · Entity 2473 | Exercise / conversionCommon Stock | 35,000 | $6.04 | $211,400.00 |
DisclosureSEC source: 0000950170-24-138441 · ownership.xml · nonDerivative · entry 1 Galligan Andrew H · CIK 0001417976 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 256,756 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The total shares reported has been adjusted for 77 shares inadvertently over reported on a Form 4 filed on June 7, 2024. Read SEC document |
| June 06, 2024 Filed Jun 7, 2024 19:06 UTC | OOMA INC OOMA · Entity 2473 | GrantCommon Stock | 19,762 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-070502 · ownership.xml · nonDerivative · entry 1 Galligan Andrew H · CIK 0001417976 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,833 F1 · shares: 100% of the total number of restricted stock units shall vest on the date of the Company's 2025 annual stockholder meeting, subject to the Reporting Person's continued service as a member of the Board. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 23:50 UTC | OOMA INC OOMA · Entity 2473 | GrantCommon Stock | 11,783 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-034665 · doc4.xml · nonDerivative · entry 1 Galligan Andrew H · CIK 0001417976 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,071 F1 · shares: 100% of the total number of restricted stock units shall vest on the date of the Company's 2024 annual stockholder meeting, subject to the Reporting Person's continued service as a member of the Board. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:51 UTC | OOMA INC OOMA · Entity 2473 | GrantCommon Stock | 11,355 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-034131 · doc4.xml · nonDerivative · entry 1 Galligan Andrew H · CIK 0001417976 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,288 F1 · shares: 100% of the total number of restricted stock units shall vest on the date of the Company's 2023 annual stockholder meeting, subject to the Reporting Person's continued service as a member of the Board. Read SEC document |
| June 02, 2021 Filed Jun 4, 2021 22:30 UTC | OOMA INC OOMA · Entity 2473 | GrantCommon Stock | 7,498 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-038371 · doc4.xml · nonDerivative · entry 1 Galligan Andrew H · CIK 0001417976 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,933 F1 · shares: 100% of the total number of restricted stock units shall vest on the date of the Company's 2022 annual stockholder meeting, subject to the Reporting Person's continued service as a member of the Board. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 16:49 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 2,311 | $121.53 | $280,855.83 |
DisclosureSEC source: 0001567619-20-011851 · doc1.xml · nonDerivative · entry 1 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,179 F1 · balance_after: Includes 12,491 restricted stock units. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 22:59 UTC | OOMA INC OOMA · Entity 2473 | GrantCommon Stock | 10,451 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-034841 · doc4.xml · nonDerivative · entry 1 Galligan Andrew H · CIK 0001417976 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,435 F1 · shares: 100% of the total number of restricted stock units shall vest on the date of the Company's 2021 annual stockholder meeting, subject to the Reporting Person's continued service as a member of the Board. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 14:48 UTC | NEVRO CORP NVRO · Entity 12422 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,000 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001567619-20-005412 · doc1.xml · derivative · entry 2 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,394 Underlying: Common Stock · 8,000 shares Expires 2021-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 14:48 UTC | NEVRO CORP NVRO · Entity 12422 | Exercise / conversionCommon Stock | 8,000 | $3.60 | $28,800.00 |
DisclosureSEC source: 0001567619-20-005412 · doc1.xml · nonDerivative · entry 1 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,490 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 16,773 restricted stock units. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 18:59 UTC | NEVRO CORP NVRO · Entity 12422 | Exercise / conversionStock Option (Right to Buy) · Derivative | 17,718 | $0.00 Strike: $63.23 | $0.00 |
DisclosureSEC source: 0001567619-20-000906 · doc1.xml · derivative · entry 3 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,718 shares Expires 2025-11-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 18:59 UTC | NEVRO CORP NVRO · Entity 12422 | SaleCommon Stock | 17,718 | $120.11 | $2,128,085.95 |
DisclosureSEC source: 0001567619-20-000906 · doc1.xml · nonDerivative · entry 2 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,490 F2 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $120.00 to $120.74, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F1 · balance_after: Includes 16,773 restricted stock units. Read SEC document |
| January 08, 2020 Filed Jan 10, 2020 18:59 UTC | NEVRO CORP NVRO · Entity 12422 | Exercise / conversionCommon Stock | 17,718 | $63.23 | $1,120,309.14 |
DisclosureSEC source: 0001567619-20-000906 · doc1.xml · nonDerivative · entry 1 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,208 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 16,773 restricted stock units. Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 12:00 UTC | NEVRO CORP NVRO · Entity 12422 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,782 | $0.00 Strike: $63.23 | $0.00 |
DisclosureSEC source: 0001567619-20-000740 · doc1.xml · derivative · entry 3 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,718 Underlying: Common Stock · 2,782 shares Expires 2025-11-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Fully vested. Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 12:00 UTC | NEVRO CORP NVRO · Entity 12422 | SaleCommon Stock | 2,782 | $120.00 | $333,840.00 |
DisclosureSEC source: 0001567619-20-000740 · doc1.xml · nonDerivative · entry 2 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,490 F2 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F1 · balance_after: Includes 16,773 restricted stock units. Read SEC document |
| January 06, 2020 Filed Jan 8, 2020 12:00 UTC | NEVRO CORP NVRO · Entity 12422 | Exercise / conversionCommon Stock | 2,782 | $63.23 | $175,905.86 |
DisclosureSEC source: 0001567619-20-000740 · doc1.xml · nonDerivative · entry 1 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,272 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 16,773 restricted stock units. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 16:23 UTC | NEVRO CORP NVRO · Entity 12422 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $63.23 | $0.00 |
DisclosureSEC source: 0001567619-19-022263 · doc1.xml · derivative · entry 3 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,500 Underlying: Common Stock · 12,000 shares Expires 2025-11-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 16:23 UTC | NEVRO CORP NVRO · Entity 12422 | SaleCommon Stock | 12,000 | $110.39 | $1,324,713.60 |
DisclosureSEC source: 0001567619-19-022263 · doc1.xml · nonDerivative · entry 2 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,490 F2 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $110 to $110.79, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F1 · balance_after: Includes 16,773 restricted stock units. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 16:23 UTC | NEVRO CORP NVRO · Entity 12422 | Exercise / conversionCommon Stock | 12,000 | $63.23 | $758,760.00 |
DisclosureSEC source: 0001567619-19-022263 · doc1.xml · nonDerivative · entry 1 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,490 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 16,773 restricted stock units. Read SEC document |
| November 11, 2019 Filed Nov 13, 2019 19:20 UTC | NEVRO CORP NVRO · Entity 12422 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $63.23 | $0.00 |
DisclosureSEC source: 0001567619-19-021254 · doc1.xml · derivative · entry 7 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,500 Underlying: Common Stock · 12,000 shares Expires 2025-11-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from November 5, 2015 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| November 11, 2019 Filed Nov 13, 2019 19:20 UTC | NEVRO CORP NVRO · Entity 12422 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,522 | $0.00 Strike: $18.00 | $0.00 |
DisclosureSEC source: 0001567619-19-021254 · doc1.xml · derivative · entry 6 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,941 Underlying: Common Stock · 6,522 shares Expires 2024-11-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: 1/48th of the shares subject to the option vest on each monthly anniversary measured from November 5, 2014 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| November 11, 2019 Filed Nov 13, 2019 19:20 UTC | NEVRO CORP NVRO · Entity 12422 | SaleCommon Stock | 1,175 | $104.74 | $123,075.14 |
DisclosureSEC source: 0001567619-19-021254 · doc1.xml · nonDerivative · entry 5 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,490 F2 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F5 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $104.61 to $104.93, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F1 · balance_after: Includes 16,773 restricted stock units. Read SEC document |
| November 11, 2019 Filed Nov 13, 2019 19:20 UTC | NEVRO CORP NVRO · Entity 12422 | SaleCommon Stock | 10,345 | $103.85 | $1,074,286.87 |
DisclosureSEC source: 0001567619-19-021254 · doc1.xml · nonDerivative · entry 4 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,665 F2 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F4 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $103.60 to $104.51, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F1 · balance_after: Includes 16,773 restricted stock units. Read SEC document |
| November 11, 2019 Filed Nov 13, 2019 19:20 UTC | NEVRO CORP NVRO · Entity 12422 | SaleCommon Stock | 7,002 | $103.31 | $723,368.92 |
DisclosureSEC source: 0001567619-19-021254 · doc1.xml · nonDerivative · entry 3 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,010 F2 · kind: The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $102.60 to $103.59, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F1 · balance_after: Includes 16,773 restricted stock units. Read SEC document |
| November 11, 2019 Filed Nov 13, 2019 19:20 UTC | NEVRO CORP NVRO · Entity 12422 | Exercise / conversionCommon Stock | 12,000 | $63.23 | $758,760.00 |
DisclosureSEC source: 0001567619-19-021254 · doc1.xml · nonDerivative · entry 2 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,012 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 16,773 restricted stock units. Read SEC document |
| November 11, 2019 Filed Nov 13, 2019 19:20 UTC | NEVRO CORP NVRO · Entity 12422 | Exercise / conversionCommon Stock | 6,522 | $18.00 | $117,396.00 |
DisclosureSEC source: 0001567619-19-021254 · doc1.xml · nonDerivative · entry 1 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,012 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 16,773 restricted stock units. Read SEC document |
| November 01, 2019 Filed Nov 5, 2019 18:27 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 1,713 | $86.63 | $148,397.19 |
DisclosureSEC source: 0001567619-19-020473 · doc1.xml · nonDerivative · entry 1 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,490 F1 · balance_after: Includes 16,773 restricted stock units. Read SEC document |
| September 23, 2019 Filed Sep 24, 2019 00:10 UTC | OOMA INC OOMA · Entity 2473 | SaleCommon Stock | 25,000 | $10.50 | $262,400.00 |
DisclosureSEC source: 0001209191-19-050510 · doc4.xml · nonDerivative · entry 1 Galligan Andrew H · CIK 0001417976 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,984 F1 · price: The range of prices for the shares of Common Stock is from $10.44 to $10.61. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price. Read SEC document |
| September 10, 2019 Filed Sep 11, 2019 21:09 UTC | OOMA INC OOMA · Entity 2473 | SaleCommon Stock | 25,000 | $12.31 | $307,655.00 |
DisclosureSEC source: 0001209191-19-049200 · doc4.xml · nonDerivative · entry 1 Galligan Andrew H · CIK 0001417976 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,984 F1 · price: The range of prices for the shares of Common Stock is from $12.17 to $12.59. The reporting person undertakes that he will provide, upon request by the staff of the U.S. Securities and Exchange Commission, full information regarding the number of securities sold at each separate price. Read SEC document |
| July 16, 2019 Filed Jul 17, 2019 18:10 UTC | NEVRO CORP NVRO · Entity 12422 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001567619-19-014943 · doc1.xml · derivative · entry 2 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,394 Underlying: Common Stock · 2,500 shares Expires 2021-09-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| July 16, 2019 Filed Jul 17, 2019 18:10 UTC | NEVRO CORP NVRO · Entity 12422 | Exercise / conversionCommon Stock | 2,500 | $3.60 | $9,000.00 |
DisclosureSEC source: 0001567619-19-014943 · doc1.xml · nonDerivative · entry 1 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,203 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 21,731 restricted stock units. Read SEC document |
| July 08, 2019 Filed Jul 9, 2019 22:04 UTC | OOMA INC OOMA · Entity 2473 | Exercise / conversionStock Option (right to buy) · Derivative | 114,943 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0000899243-19-019393 · doc4.xml · derivative · entry 4 Galligan Andrew H · CIK 0001417976 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 114,943 shares Expires 2019-09-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| July 08, 2019 Filed Jul 9, 2019 22:04 UTC | OOMA INC OOMA · Entity 2473 | Exercise / conversionStock Option (right to buy) · Derivative | 19,157 | $0.00 Strike: $0.90 | $0.00 |
DisclosureSEC source: 0000899243-19-019393 · doc4.xml · derivative · entry 3 Galligan Andrew H · CIK 0001417976 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,157 shares Expires 2019-09-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| July 08, 2019 Filed Jul 9, 2019 22:04 UTC | OOMA INC OOMA · Entity 2473 | Exercise / conversionCommon Stock | 114,943 | $0.90 | $103,448.70 |
DisclosureSEC source: 0000899243-19-019393 · doc4.xml · nonDerivative · entry 2 Galligan Andrew H · CIK 0001417976 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,984 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 08, 2019 Filed Jul 9, 2019 22:04 UTC | OOMA INC OOMA · Entity 2473 | Exercise / conversionCommon Stock | 19,157 | $0.90 | $17,241.30 |
DisclosureSEC source: 0000899243-19-019393 · doc4.xml · nonDerivative · entry 1 Galligan Andrew H · CIK 0001417976 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,041 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2019 Filed Jun 12, 2019 21:29 UTC | OOMA INC OOMA · Entity 2473 | GrantCommon Stock | 9,607 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-036475 · doc4.xml · nonDerivative · entry 1 Galligan Andrew H · CIK 0001417976 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,884 F1 · shares: 100% of the total number of restricted stock units shall vest on the date of the Company's 2020 annual stockholder meeting, subject to the Reporting Person's continued service as a member of the Board. Read SEC document |
| May 28, 2019 Filed May 30, 2019 17:39 UTC | NEVRO CORP NVRO · Entity 12422 | GrantCommon Stock | 8,564 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-19-012439 · doc1.xml · nonDerivative · entry 1 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,703 F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 50% of the RSUs vest on June 4, 2020 and the remaining 50% vest on June 4, 2021, subject to the Reporting Person's continued service to the issuer. F2 · balance_after: Includes 21,731 RSUs. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 11:28 UTC | NEVRO CORP NVRO · Entity 12422 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,004 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001567619-19-000765 · doc1.xml · derivative · entry 2 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,004 shares Expires 2020-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
| January 04, 2019 Filed Jan 8, 2019 11:28 UTC | NEVRO CORP NVRO · Entity 12422 | Exercise / conversionCommon Stock | 11,004 | $1.44 | $15,845.76 |
DisclosureSEC source: 0001567619-19-000765 · doc1.xml · nonDerivative · entry 1 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,139 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 13,167 restricted stock units. Read SEC document |
| November 01, 2018 Filed Nov 2, 2018 19:03 UTC | NEVRO CORP NVRO · Entity 12422 | Tax withholdingCommon Stock | 2,457 | $49.40 | $121,375.80 |
DisclosureSEC source: 0001567619-18-005040 · doc1.xml · nonDerivative · entry 1 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,135 F1 · balance_after: Includes 13,167 restricted stock units. Read SEC document |
| July 18, 2018 Filed Jul 20, 2018 18:02 UTC | NEVRO CORP NVRO · Entity 12422 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,400 | $0.00 Strike: $1.44 | $0.00 |
DisclosureSEC source: 0001140361-18-033064 · doc1.xml · derivative · entry 2 Galligan Andrew H · CIK 0001417976 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,004 Underlying: Common Stock · 7,400 shares Expires 2020-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 100% of the shares subject to the option are fully vested and exercisable. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.